Ivonescimab is an investigational bispecific antibody designed to simultaneously target programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). By combining immune-checkpoint inhibition with VEGF blockade in a single molecule, ivonescimab is being developed as a novel approach to cancer immunotherapy.
Ivonescimab is also known as SMT112 and is being investigated primarily in oncology, particularly in non-small cell lung cancer (NSCLC).
Ivonescimab is a specialized biological pharmaceutical ingredient requiring recombinant expression and advanced purification and characterization technologies.
Quality evaluation for a bispecific antibody includes assessment of identity, purity, aggregation, charge variants, molecular integrity, target binding, biological potency, glycosylation, host-cell proteins, residual DNA, endotoxins and sterility.
Molecule Type: Bispecific Monoclonal Antibody
Target 1: PD-1
Target 2: VEGF
Drug Class: Antineoplastic / Immunotherapy
Pharmacological Class: PD-1 / VEGF Bispecific Antibody
Therapeutic Area: Oncology
Primary Development Area: Non-Small Cell Lung Cancer
Ivonescimab is designed to simultaneously interact with PD-1 on immune cells and VEGF in the tumor microenvironment.
Its dual-targeting approach is intended to:
Ivonescimab is being investigated in oncology, particularly for:
As an investigational medicine, its clinical applications should not be presented as established approved indications unless supported by the applicable regulatory authority.
Unlike conventional monoclonal antibodies directed against a single target, ivonescimab is designed to engage two biological targets simultaneously.
This dual-targeting strategy is intended to integrate:
Immune checkpoint inhibition + VEGF pathway blockade
within a single therapeutic molecule.
Typical manufacturing of a bispecific antibody such as ivonescimab may involve:
Ivonescimab quality evaluation may include:
Ivonescimab drug substance or drug product should be stored according to validated stability data and applicable investigational-product requirements. Controlled temperature conditions and protection from inappropriate light exposure are important for maintaining antibody integrity.
Ivonescimab is relevant to research involving:
Ivonescimab is an investigational PD-1/VEGF bispecific antibody developed for oncology applications. Its mechanism is designed to combine immune-checkpoint blockade and VEGF inhibition in a single biological therapeutic, with development focused particularly on non-small cell lung cancer and other solid tumors.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |